Krystal Biotech is a fully integrated, commercial-stage global biotechnology enterprise dedicated to discovering, developing, and commercializing innovative genetic medicines for patients suffering from severe diseases with high unmet medical needs. Utilizing its proprietary, non-replicating engineered viral vector platform, the company designs localized therapies that can be repeatedly administered to treat root genetic causes without provoking adverse systemic immune responses. Its primary commercial success is VYJUVEK, designed for dystrophic epidermolysis bullosa, alongside a robust pipeline targeting respiratory conditions like cystic fibrosis, oncology applications such as non-small cell lung cancer, and aesthetic or ophthalmic indications, establishing the firm as a pioneer in translational genetic medicine.